The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction
Open accessAbstract
Background: ST ‐segment–elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 blockade with anakinra significantly reduced the area under the curve for hsCRP (high sensitivity C‐reactive protein) levels during the first 14 days in patients with ST ‐segment–elevation myocardial infarction (VCUART3 [Virginia Commonwealth University Anakinra Remodeling Trial 3]). Methods and Results: We conducted a randomized, placebo‐controlled, double‐blind, clinical trial in 99 patients with ST ‐segment–elevation myocardial infarction in which patients were assigned to 2 weeks treatment with anakinra once daily (N=33), anakinra twice daily (N=31), or placebo (N=35). hsCRP area under the curve was significantly lower in patients receiving anakinra versus placebo (median, 67 [interquartile range, 39–120] versus 214 [interquartile range, 131–394] mg·day/L; P <0.001), without significant differences between the anakinra arms. No significant differences were found between anakinra and placebo groups in the interval changes in left ventricular end‐systolic volume (median, 1.4 [interquartile range, −9.8 to 9.8] versus −3.9 [interquartile range, −15.4 to 1.4] mL; P =0.21) or left ventricular ejection fraction (median, 3.9% [interquartile range, −1.6% to 10.2%] versus 2.7% [interquartile range, −1.8% to 9.3%]; P =0.61) at 12 months. The incidence of death or new‐onset heart failure or of death and hospitalization for heart failure was significantly lower with anakinra versus placebo (9.4% versus 25.7% [ P =0.046] and 0% versus 11.4% [ P =0.011], respectively), without difference between the anakinra arms. The incidence of serious infection was not different between anakinra and placebo groups (14% versus 14%; P =0.98). Injection site reactions occurred more frequently in patients receiving anakinra (22%) versus placebo (3%; P =0.016). Conclusions: In patients presenting with ST ‐segment–elevation myocardial infarction, interleukin‐1 blockade with anakinra significantly reduces the systemic inflammatory response compared with placebo. Clinical Trial Registration: URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 01950299.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
Cyclosporine before PCI in Patients with Acute Myocardial Infarction
Cung, T.-T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., Bonnefoy-Cudraz, E., Guérin, P., Elbaz, M., Delarche, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505489 · Cited by 713
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
Self-citationAnti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Everett, B. M., Cornel, J. H., Lainscak, M., Anker, S. D., Abbate, A., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2019) · Circulation · doi:10.1161/circulationaha.118.038010 · Cited by 658
Self-citationLong-Term Trends in the Incidence of Heart Failure After Myocardial Infarction
Velagaleti, R. S., Pencina, M. J., Murabito, J. M., Wang, T. J., Parikh, N. I., D'Agostino, R. B., Levy, D., Kannel, W. B., & Vasan, R. S. (2008) · Circulation · doi:10.1161/circulationaha.108.784215 · Cited by 535
Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G. L., Van Tassell, B. W., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 415
Self-citationAbbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., Oddi, C., Roberts, C. S., Melchior, R. D., Mueller, G. H., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.287 · Cited by 393
Self-citationEzekowitz, J. A., Kaul, P., Bakal, J. A., Armstrong, P. W., Welsh, R. C., & McAlister, F. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.067 · Cited by 371
Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi-Zoccai, G. G. L., Houser, J.-E., Qureshi, I. Z., Ownby, E. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.740233 · Cited by 360
Self-citation
Cited by
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
Self-citationInterleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A. J. B., Zurke, Y.-X., & Monaco, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 425
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
Metadata
- Authors
- Abbate, A., Trankle, C. R., Buckley, L. F., Lipinski, M. J., Appleton, D., Kadariya, D., Canada, J. M., Carbone, S., Roberts, C. S., Abouzaki, N., Melchior, R., Christopher, S., Turlington, J., Mueller, G., Garnett, J., Thomas, C., Markley, R., Wohlford, G. F., Puckett, L., Medina de Chazal, H., Chiabrando, J. G., Bressi, E., Del Buono, M. G., Schatz, A., Vo, C., Dixon, D. L., Biondi‐Zoccai, G. G., Kontos, M. C., & Van Tassell, B. W.
- Venue
- Journal of the American Heart Association
- Published
- 2020-03-03
- Volume
- 9
- Issue
- 5
- Pages
- e014941-e014941
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W3009251297
- Cited by
- 300
- References
- 24
- FWCI
- 22.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction. https://app.cochat.ai/papers/10.1161/jaha.119.014941
- The paper
- Abbate, A., Trankle, C. R., Buckley, L. F., Lipinski, M. J., Appleton, D., Kadariya, D., Canada, J. M., Carbone, S., Roberts, C. S., Abouzaki, N., Melchior, R., Christopher, S., Turlington, J., Mueller, G., Garnett, J., Thomas, C., Markley, R., Wohlford, G. F., Puckett, L., . . . Van Tassell, B. W. (2020). Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.119.014941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.